The Use of Low Molecular Weight Heparin in Traumatic Brain Injury
To study the safety and efficacy of early administration of Low Molecular Weight Heparin to patients with traumatic brain injury.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||The Use of Low Molecular Weight Heparin in Traumatic Brain Injury|
- Safety: Assess if early administration of LMWH exacerbates intracranial hemorrhage.
- Efficacy: Demonstrate effectiveness of dosing regimen in preventing VTE.
|Study Start Date:||December 2002|
|Estimated Study Completion Date:||August 2005|
Venous thromboembolic (VTE) prophylaxis in trauma patients is a critical clinical problem. Patients with traumatic brain injury usually have effective VTE prophylaxis withheld secondary to concerns of exacerbating intracranial hemorrhage. This study examines the safety and efficacy of early administration (within 24 hrs of admission) of low molecular weight heparin to this patient population with very high VTE risk.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00170378
|United States, Minnesota|
|Hennepin County Medical Center|
|Minneapolis, Minnesota, United States, 55415|
|Principal Investigator:||John K. Cumming, M.D.||Hennepin County Medical Center/MinneapolisMRF|